ICD code T86.21 – Heart transplant rejection

Key takeaways

T86.21 is a billable ICD-10-CM code for heart transplant rejection, valid FY2016 through FY2027, under Chapter 19 block T80-T88.

Z94.1 (heart transplant status) is not reported with T86.21, because Guideline I.C.21.c.3 says the complication code already identifies a heart transplant patient.

T86.21 (rejection) and T86.22 (failure) each need the physician’s own statement. Coders cannot make that clinical call from test results.

Pabau, the practice management platform we build, submits claims through Claim.MD with eligibility checks, authorization cases and electronic remittance advice (ERA) tracking.

ICD-10 Code T86.21: Definition, billable status, and code hierarchy

ICD-10 Code T86.21 is the designated billable diagnosis code for heart transplant rejection within the ICD-10-CM classification system. It is confirmed billable for FY2016 through FY2027 per the CMS ICD-10 coding and billing guidance.

The code sits within Chapter 19 (Injury, poisoning and certain other consequences of external causes). Its block is T80-T88 (Complications of surgical and medical care, not elsewhere classified). Its parent code is T86.2 (Complications of heart transplant), which is itself not billable. T86.21 is the correct code when the physician has documented rejection as the specific complication.

What heart transplant rejection means clinically

Heart transplant rejection occurs when the recipient’s immune system identifies donor heart tissue as foreign and mounts an attack against it. Three rejection types are recognized clinically, each with different timelines, mechanisms, and documentation implications for coders.

• Acute cellular rejection: T-cell mediated, and typically seen within the first year after transplant. Confirmed by endomyocardial biopsy and graded using the International Society for Heart and Lung Transplantation (ISHLT) scale. It is the most common type coded to T86.21.
• Antibody-mediated rejection (AMR): Driven by donor-specific antibodies, and can occur at any time. Diagnosed through biopsy plus serology. Requires explicit physician documentation stating “antibody-mediated rejection” for T86.21 to be supported.
• Chronic rejection: Manifests as cardiac allograft vasculopathy (CAV), which has its own code, T86.290, rather than T86.21. See the CAV section below.

ICD-10-CM does not subdivide T86.21 by rejection type or ISHLT grade. The code captures all acute rejection episodes, regardless of grade or mechanism, as long as the physician has documented rejection as the clinical determination.

How heart transplant rejection is diagnosed for coding purposes

Endomyocardial biopsy (EMB) is the gold standard for confirming heart transplant rejection. Coders don’t interpret the diagnostic pathway themselves. They need to know it so they can tell what documentation the record must contain before T86.21 is assigned.

The ResDAC ICD coding guidance notes that diagnosis codes must be grounded in physician documentation, not test results alone. A biopsy showing ISHLT Grade 2R (moderate rejection) supports the code only with the physician’s note. That note must state that rejection is occurring and treatment is starting.

The diagnostic sequence coders typically see in the record:

1. Surveillance or symptomatic biopsy performed (CPT 93505)
2. ISHLT grade reported by pathology (Grade 1R, 2R or 3R for cellular rejection, pAMR 1-3 for antibody-mediated)
3. Physician interprets biopsy results and documents rejection as a clinical finding
4. Physician notes treatment initiated (pulse-dose steroids, adjustment of immunosuppression, plasmapheresis for AMR)
5. Attending physician attests to the rejection diagnosis in the discharge summary or progress note

Step 5 is where claims fail. A biopsy result in the record with no attending attestation is not sufficient. Clinical documentation integrity (CDI) specialists should query when the biopsy grade is elevated but the physician note reads only “transplant follow-up” or “graft dysfunction.”

ICD-10-CM code hierarchy for heart transplant complications

Knowing where T86.21 sits helps coders pick the right sibling code when the note describes something other than rejection. Category T86 covers complications of all transplanted organs and tissue. Subcategory T86.2 narrows that to the transplanted heart, and T86.298 takes any named complication the other codes don’t cover.

T86.2 itself is never reported on a claim. Payers will reject any bill carrying the parent code without the child-level specificity that T86.20 through T86.298 provide. T86.20 is a last resort for a note that names no specific complication, so a query usually beats assigning it.

The T86.2 codes also carry a “use additional code” note for other transplant complications. Examples include graft-versus-host disease (D89.81-), post-transplant lymphoproliferative disorder (D47.Z1) and malignancy associated with a transplanted organ (C80.2).

T86.21 vs T86.22 vs T86.23: Choosing the right code

T86.21 (rejection), T86.22 (failure), T86.23 (infection) and the T86.29- codes are told apart by the physician’s own statement. Coders must not make that clinical call themselves. The decision path below starts from the wording of the attending note.

Work down the rows in order and stop at the first match. The table below adds the documentation each code needs and the note that should trigger a CDI query.

With T86.22, the deciding factor is irreversibility. Rejection implies the immune event is being treated and the graft may recover. Failure means the graft can no longer perform its function. If the physician documents both rejection and failure, both codes may be reported. Confirm sequencing against AHA Coding Clinic.

Additional codes to report alongside T86.21

ICD-10-CM Official Guidelines Section I.C.21.c.3 says Z94.1 (heart transplant status) should not be used with a code from subcategory T86.2. The status code adds no information, because the complication code already shows the patient has a transplanted heart. The additional codes that do belong on a T86.21 claim describe other complications, drug therapy and drug effects.

• Z94.1 (Heart transplant status): Not reported with T86.21 or any other T86.2- code. Z94.1 is for encounters where the transplant matters but no complication of it is documented.
• Other transplant complications: When the physician documents them, add graft-versus-host disease (D89.81-), post-transplant lymphoproliferative disorder (D47.Z1) or malignancy associated with the transplanted organ (C80.2).
• Immunosuppressive therapy codes: Long-term immunosuppressant use is reported from subcategory Z79.6-. Use Z79.621 for calcineurin inhibitors such as tacrolimus and cyclosporine, and Z79.624 for inhibitors of nucleotide synthesis such as mycophenolate. Z79.899 is not the code for these agents.
• Cyclosporine/tacrolimus toxicity: When the drug was taken as prescribed, code the manifestation plus T45.1X5A (adverse effect of antineoplastic and immunosuppressive drugs, initial encounter). T45.1X1A is the accidental poisoning code and applies only when the drug was taken incorrectly. Toxicity and rejection need different codes and different physician statements.
• Cardiac allograft vasculopathy: If CAV is present as a separate condition, add T86.290 rather than a second rejection code. Its Excludes1 note bars I25.75-, I25.76- and I25.81- on the same claim. See the CAV section below.

Documentation requirements for T86.21

Sufficient documentation for T86.21 must come from the treating physician, not from pathology or nursing notes alone. CDI specialists and coders reviewing records for this code should look for the following elements.

Physician documentation checklist

• Explicit statement of “rejection” or “heart transplant rejection” in the attending physician’s note (not only in the biopsy report)
• Biopsy grade documented and attributed to the current encounter (ISHLT Grade 1R, 2R or 3R, or pAMR for antibody-mediated rejection)
• Rejection type specified where distinguishable: acute cellular rejection vs. antibody-mediated rejection
• Treatment initiated and documented: pulse steroids, plasmapheresis, intravenous immunoglobulin, or adjustment of baseline immunosuppression
• Transplant date and donor information present in the medical record (confirms post-transplant status)
• For a surveillance biopsy with Grade 1R (no treatment needed), the physician must state whether rejection is present or absent. Without that statement, coders cannot assign T86.21.

CDI query language that works: “The biopsy performed on [date] showed [Grade]. Please clarify in the medical record whether heart transplant rejection is present and whether treatment is being initiated.” This avoids leading the physician toward a particular code while still generating the documentation coders need.

Payer requirements and billing for heart transplant rejection

Medicare covers medically necessary treatment for heart transplant rejection under the same inpatient and outpatient rules that apply to post-transplant care generally. Commercial payers typically follow Medicare’s national coverage framework but add local coverage requirements. Verifying current payer-specific Local Coverage Determinations (LCDs) before claim submission reduces avoidable denials.

Prior authorization is commonly required for inpatient admissions triggered by a rejection episode. For readmissions within 30 days of a prior transplant-related discharge, some payers apply bundled payment policies that affect how T86.21 is reported. Submit T86.21 as the principal diagnosis for rejection-related inpatient stays, with any additional complication, drug-effect and immunosuppressant codes following. Z94.1 stays off the claim.

Common claim denial reasons for T86.21

T86.21 denials follow a predictable pattern, and each cause below has a fix you can apply before submission. The denial codes on the remittance tell you which one hit. Structured denial management workflows show transplant programs which reason recurs most, so CDI work goes there first.

• Documentation that never says “rejection”: A note reading “transplant complication” or “graft dysfunction, cause unclear” does not support T86.21. The physician must state rejection explicitly, so query before coding.
• Sibling-code mix-ups: Failure (T86.22), infection (T86.23) and CAV (T86.290) each have their own code. A claim coded as rejection when the note describes one of those does not match the record.
• Z94.1 added to the claim: Guideline I.C.21.c.3 says not to report the status code with a T86.2- code. Remove it before submission rather than adding it to “support” the complication code.
• No biopsy result linked to the encounter: Some payers require the biopsy result to appear in the record for the same episode. If the biopsy was performed at another facility and never forwarded, the rejection admission has no biopsy evidence on file.
• ICD-9 crosswalk errors on legacy systems: Older billing systems that auto-crosswalk from ICD-9 may pull in T86.20 (unspecified) rather than T86.21. Verify the specific child code appears on the claim before submission.
• Sequencing errors: When the rejection episode is the reason for admission, T86.21 should be the principal diagnosis. Listing it as a secondary code behind an administrative code or a symptom code inverts the sequencing and triggers review.
• Wrong code version year: Claims submitted with an ICD-10-CM code set that does not match the date of service are rejected. T86.21 has been valid since FY2016. Confirm the claim uses the FY-appropriate code set per the CDC/NCHS ICD-10-CM lookup tool.

Cardiac allograft vasculopathy: Why it is not T86.21

Cardiac allograft vasculopathy (CAV) is a chronic immune-mediated process that causes diffuse coronary artery narrowing in the transplanted heart. It is sometimes called “chronic rejection,” but it is not coded as T86.21.

CAV is a separate disease process from acute rejection episodes, and it has its own code, T86.290. T86.290 carries an Excludes1 note for atherosclerosis of the coronary arteries of a transplanted heart (I25.75-, I25.76-, I25.81-). Those codes are not reported alongside it.

Assigning T86.21 to a CAV encounter misrepresents the clinical picture and can trigger payer audit queries. T86.21 implies an acute immune event that needs active anti-rejection treatment, while CAV involves chronic vascular management.

When an acute rejection episode and CAV are both present in the same encounter, code each one. Use T86.21 for the acute rejection and T86.290 for CAV. Physician documentation must support both as concurrent conditions to assign both codes. Verify specific code assignment against current AHA Coding Clinic guidance, as coding practice for CAV continues to evolve.

ICD-9 to ICD-10 crosswalk for heart transplant rejection

Practices reviewing pre-2015 records or reconciling legacy claims encounter ICD-9-CM codes for transplant complications. The T86 category maps primarily from the ICD-9-CM 996 series (complications of transplanted organ). Per the AAPC ICD-10-CM coding reference, the general equivalence mapping (GEM) from CMS identifies the following approximate crosswalk.

The GEM is not a 1:1 crosswalk. ICD-9 code 996.83 mapped to the entire heart transplant complication category. ICD-10-CM requires specificity (rejection, failure, infection, CAV or other) that ICD-9 did not require. Always verify crosswalk assignments against official CMS GEM files rather than relying on system auto-conversion.

How Pabau supports clean T86.21 claims

Transplant billing teams usually find a T86.21 coding error after the denial arrives, by rereading the attending note against the code list line by line.

Pabau sends claims through Claim.MD, our US clearinghouse partner. That Claim.MD clearinghouse connection submits CMS-1500 claims to thousands of US payers, with eligibility checks before submission.

With Pabau’s claims management software, billing teams store each insurer authorization as a case, so the approval for a rejection admission sits with its claim. Each T86.21 claim is then tracked through to ERA receipt, while the attending note is still easy to query.

Streamline transplant complication billing

Pabau’s claims management platform connects to thousands of US payers through Claim.MD and tracks every T86.21 claim through to electronic remittance. Coding teams spend less time chasing claims and more time on documentation quality.

Book a demo

Conclusion

Heart transplant rejection coding turns on the attending physician’s own words. When the note states rejection, T86.21 is supported. When it says only “transplant complication,” query before you pick between T86.21, T86.22, T86.23 and the T86.29- codes.

Leave Z94.1 off the claim, because the complication code already tells the payer this is a heart transplant patient. Spend that effort on the codes that add information instead, such as the Z79.6- drug therapy and any other transplant complication.

Pabau’s clean claim submission through Claim.MD checks patient eligibility before a claim goes out. Each T86.21 claim is then tracked through to payer ERA receipt. Book a demo to see how Pabau keeps transplant complication claims clean from note to remittance.

Continue your research

Need a structured framework for tracking claim denials? Denial management in healthcare covers how to categorize, track, and appeal claim denials systematically.

Submitting transplant claims electronically for the first time? Claim.MD clearinghouse overview explains how electronic claim submission works across thousands of US payers.

Want to understand how ERA remittances work after claim submission? Electronic remittance advice breaks down how to read and reconcile ERA files for transplant complication codes.

Does the note link an infection to the new heart? ICD-10 code T86.23 covers heart transplant infection and the additional code that identifies the infection.

Coronary narrowing labeled as chronic rejection? ICD-10 code T86.290 explains how cardiac allograft vasculopathy is coded and which I25 codes it excludes.

Frequently asked questions